{"schema_version":"1","generated_at":"2026-11-10T13:27:11.471Z","data_as_of":null,"url":"https://www.findmykol.com/kol/bryan-mehlhaff","json_url":"https://www.findmykol.com/kol/bryan-mehlhaff/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"bryan-mehlhaff","name":"Bryan Mehlhaff","credential":"MD","specialty":"Urology","specialty_raw":"Urology","therapeutic_area":"Genitourinary","therapeutic_areas":["Genitourinary"],"institution":"Oregon Urology Institute","institution_url":"https://www.findmykol.com/institution/oregon-urology-institute","city":"Springfield","state":"OR","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1518978204","openalex":"A5011344837"},"summary":"Bryan Mehlhaff is a Genitourinary physician affiliated with Oregon Urology Institute. OpenAlex indexes 34 publications with 418 citations (h-index 10).","overview":null,"focus":{"indications":[],"research_topics":["Genitourinary"]},"scholarship":{"works_count":34,"cited_by_count":418,"h_index":10,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":40,"program_years":{"first":2021,"last":null},"rows_total":116,"shown":3,"withheld":113,"rows":[{"payer":"Pfizer","program_year":2025,"amount_usd":462071.82,"payment_count":10,"source_url":"https://openpaymentsdata.cms.gov/search?query=1518978204"},{"payer":"Novartis","program_year":2025,"amount_usd":453223.88,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1518978204"},{"payer":"Dendreon","program_year":2025,"amount_usd":266521.48,"payment_count":12,"source_url":"https://openpaymentsdata.cms.gov/search?query=1518978204"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1518978204","source":"payments"},"publications":{"total":34,"shown":5,"withheld":29,"matched_by":"OpenAlex author record","recent":[{"title":"Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","year":2026,"journal":"The Lancet Oncology","source_url":"https://doi.org/10.1016/s1470-2045(26)00071-9","status":"verified"},{"title":"EXTENDED FOLLOW-UP SHOWS ACCUMULATING BENEFIT FOR PATIENTS TREATED WITH AGLATIMAGENE BESADENOVEC (CAN-2409) +PRODRUG IN COMBINATION WITH STANDARD OF CARE EXTERNAL BEAM RADIATION (EBRT) IN MEN WITH LOCALIZED PROSTATE CANCER: UPDATE FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 3 CLINICAL TRIAL","year":2026,"journal":"The Journal of Urology","source_url":"https://doi.org/10.1097/01.ju.0001192572.07890.f8.01","status":"verified"},{"title":"Overall survival in metastatic castration-resistant prostate cancer (mCRPC): A retrospective electronic medical record analysis of men treated with sipuleucel-T in community urology over 14 years.","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.e17041","status":"verified"},{"title":"Metastatic Castration-Resistant Prostate Cancer: 14-Year Real-World Sipuleucel-T Outcomes in Urology","year":2025,"journal":"Research Square","source_url":"https://doi.org/10.21203/rs.3.rs-7348924/v1","status":"verified"},{"title":"Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2024.42.4_suppl.15","status":"verified"}],"source":"works"},"similar":[{"name":"Kevin Krughoff","slug":"kevin-krughoff","institution":"Oregon Urology Institute","specialty":"Urology","url":"https://www.findmykol.com/kol/kevin-krughoff","json_url":"https://www.findmykol.com/kol/kevin-krughoff/profile.json"},{"name":"Howard Scher","slug":"howard-scher","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/howard-scher","json_url":"https://www.findmykol.com/kol/howard-scher/profile.json"},{"name":"Toni Choueiri","slug":"toni-choueiri","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/toni-choueiri","json_url":"https://www.findmykol.com/kol/toni-choueiri/profile.json"},{"name":"Robert Motzer","slug":"robert-motzer","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/robert-motzer","json_url":"https://www.findmykol.com/kol/robert-motzer/profile.json"},{"name":"Fred Saad","slug":"fred-saad","institution":"Centre hospitalier de l'Université de Montréal (CHUM)","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/fred-saad","json_url":"https://www.findmykol.com/kol/fred-saad/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":113,"publications":29}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}